MarketPulse

precision oncology

5 articles
The Motley FoolThe Motley Fool··Andy Gould

Swiss Biotech Fund Doubles Down on Relay With $6M Stake Bet

Swiss biotech fund Nextech Invest increases Relay Therapeutics stake by $6.1M, signaling institutional confidence in company's computational platform and clinical pipeline.
RVMDRVMDWRLAYXBIIBBinstitutional buyingbiotech investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Trims $104M Nuvalent Stake as Cancer Drug Developer Surges 30%

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.
ABBVNUVLTERNBMRNFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Celcuity With $170M Stake as Stock Soars 1,040%

Deerfield Management increased its Celcuity stake by $80.6M in Q4, bringing total position to $170.95M. Stock surged 1,040% amid FDA review of breast cancer drug gedatolisib.
CELCFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Castle Biosciences, Inc.

Castle Biosciences' Melanoma Test Validates Risk Stratification in Landmark 912-Patient Study

Castle Biosciences' DecisionDx-Melanoma test confirmed 2.6% nodal positivity in 912 patients predicted low-risk, supporting safe SLNB avoidance and validating the diagnostic platform.
CSTLgene expression profileprecision oncology
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Launches Global Trial for Dual-Action Tumor Therapy HMPL-A580

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.
HCMclinical developmentsolid tumors